Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Resmetirom is the first drug to show both MASH resolution and fibrosis improvement in a late-stage clinical trial.
People diagnosed with fatty liver disease before age 45 were about 50% more likely to develop cancer.
For both adolescents and adults, body mass index and waist circumference were linked to greater risk of MASLD.
Losing weight and reversing obesity might seem straightforward: Eat fewer calories than you burn. But that’s not as easy as it sounds.
A personalized approach to diagnosis and treatment is needed when viral hepatitis and fatty liver disease coexist.
More people who participated in a specialized program lost weight compared with those who received standard care.
Adolescents who utilized food assistance programs had better protection against MASLD.
MASLD and MASH can lead to liver fibrosis, cirrhosis and liver cancer.
An increase in fatty liver disease could double liver cancer cases and nearly triple the need for transplants by 2050.
Name change emphasizes the role of metabolic dysfunction in fatty liver disease.
Hepatocellular carcinoma among people with HCV fell after the debut of direct-acting antivirals, but cases are rising for other groups.
Funding will support research on conditions including fatty liver disease, liver cancer, asthma and chronic kidney disease.
About 63% of American adults consume at least one or more sugar-sweetened beverages daily.
For people with NAFLD or NASH, treating metabolic problems may offer benefits beyond liver disease.
In 2022, fatty liver disease accounted for nearly a quarter of all liver cancer cases on the transplant waiting list.
Colorectal cancer often spreads to the liver, especially when patients have fatty liver disease. New research may help explain this link.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.